Effect of Xuebijing infusion on diaphragmatic function in critical ill patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016065

Enrollment

Unknown

Registered

2018-05-09

Start date

2018-05-01

Completion date

Unknown

Last updated

2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

1:Xuebijing injection

2:normal salion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to Sepsis 3.0 diagnostic criteria, aged 18 to 75 years old; SOFA score 2 -13; signed informed consent.

Exclusion criteria

Exclusion criteria: The time for the diagnosis of Sepsis was more than 48 hours; pregnant women, lactation women, body mass index 30; the severe primary disease affecting survival; the single SOFA score of the liver or kidney was more than 3; in the last 6 months, the use of immunosuppressive agents, or organ transplant recipients, continued to use hormone and converted tomore than 20mg/ days methylprednisolone on the first 7 days of the group. Those who had participated in other clinical trials within 30 days; the researchers judged that they could not complete or should not participate in the study

Design outcomes

Primary

Measure	Time frame
diaphragmatic function;	—

Countries

China

Contacts

Public ContactTao YU

Wannan Medical College First Affiliated Hospital, Yijishan Hospital

yutao197808@163.com+86 18855392038

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026